Nine-month follow-up of the insulin receptor signalling cascade in the brain of streptozotocin rat model of sporadic Alzheimer’s disease

Journal of Neural Transmission

Volumn 122, Issue 4, 2015, Pages 565-576

  Osmanovic Barilar, J ^a   Knezovic, A ^a   Grunblatt E ^b   Riederer, P ^c   Salkovic Petrisic, M ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alzheimer; Brain; IDE; Insulin signalling; Streptozotocin; Tau

Indexed keywords

GLYCOGEN SYNTHASE KINASE 3BETA; INSULIN RECEPTOR; INSULINASE; MESSENGER RNA; STREPTOZOCIN; TAU PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; MAPT PROTEIN, RAT;

ACUTE TOXICITY; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DOWN REGULATION; FOLLOW UP; MALE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; RAT; SIGNAL TRANSDUCTION; SPORADIC ALZHEIMER DISEASE; UPREGULATION; ANIMAL; DISEASE MODEL; HIPPOCAMPUS; METABOLISM; PHOSPHORYLATION; RANDOMIZATION; TIME; WISTAR RAT;

ALZHEIMER DISEASE; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FOLLOW-UP STUDIES; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INSULYSIN; MALE; PHOSPHORYLATION; RANDOM ALLOCATION; RATS, WISTAR; RECEPTOR, INSULIN; RNA, MESSENGER; SIGNAL TRANSDUCTION; STREPTOZOCIN; TAU PROTEINS; TIME FACTORS;

EID: 84926215322     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-014-1323-y     Document Type: Article

References (60)

1. Agrawal R, Mishra B, Tyagi E, Nath C, Shukla R (2010) Effect of curcumin on brain insulin receptors and memory functions in STZ (ICV) induced dementia model of rat. Pharmacol Res 61:247–252
2. Agrawal R, Tyagi E, Shukla R, Nath C (2011) Insulin receptor signaling in rat hippocampus: a study in STZ (ICV) induced memory deficit model. Eur Neuropsychopharmacol 21:261–273
3. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer’s disease: seminar. Lancet 368:387–403
4. Cardoso S, Correia S, Santos RX, Carvalho C, Santos MS, Oliveira CR, Perry G, Smith MA, Zhu X, Moreira PI (2009) Insulin is a two-edged knife on the brain. J Alzheimers Dis 18:483–507
5. Chen Y, Liang Z, Blanchard J, Dai CL, Sun S, Lee MH, Grundke-Iqbal I, Iqbal K, Liu F, Gong CX (2013) A non-transgenic mouse model (icv-STZ mouse) of Alzheimer’s disease: similarities to and differences from the transgenic model (3xTg-AD mouse). Mol Neurobiol 47:711–725
6. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, Roth RA, Schellenberg GD, Jin LW, Kovacina KS, Craft S (2003) Reduced hippocampal insulin-degrading enzyme in late-onset Alzheimer’s disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162:313–319
7. Czech MP, Corvera S (1999) Signaling mechanisms that regulate glucose transport. J Biol Chem 274:1865–1868
8. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer’s disease. J Alzheimers Dis 10:89–109
9. Deng Y, Li B, Liu Ying, Iqbal K, Grundke-Iqbal I, Gong CX (2009) Dysregulation of Insulin signaling, glucose transporters, O-GlcNAcylation, and phosphorylation of tau and neurofilaments in the brain: implication for Alzheimer’s Disease. Am J Pathol 175:2089–2098
10. Doble BW, Woodgett JR (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci 116:1175–1186
11. Duelli R, Schrock H, Kuschinsky W, Hoyer S (1994) Intracerebroventricular injection of streptozotocin induces discrete local changes in cerebral glucose utilization in rats. Int J Dev Neurosci 12:737–743
12. Ferrer I, Blanco R, Carmona M, Ribera R, Goutan E, Puig B, Rey MJ, Cardozo A, Viñals F, Ribalta T (2001) Phosphorylated map kinase (ERK1, ERK2) expression is associated with early tau deposition in neurones and glial cells, but not with increased nuclear DNA vulnerability and cell death, in Alzheimer disease, Pick’s disease, progressive supranuclear palsy and corticobasal degeneration. Brain Pathol 11:144–158
13. Frölich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, Muschner D, Thalheimer A, Türk A, Hoyer S, Zöchling R, Boissl KW, Jellinger K, Riederer P (1998) Brain insulin and insulin receptors in aging and Alzheimer’s disease. J Neural Transm 105:423–438
14. Gasparini L, Xu H (2003) Potential roles of insulin and IGF-1 in Alzheimer’s disease. Trends Neurosci 26:404–406
15. Goedert M, Spillantini MG (2006) A century of Alzheimer’s disease. Science 314:777–781
16. Grünblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S (2007) Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem 101:757–770
17. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI (1986) Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci U S A. 83:4913–4917
18. Henneberg N, Hoyer S (1995) Desensitization of the neuronal insulin receptor: a new approach in the etiopathogenesis of late-onset sporadic dementia of the Alzheimer type (SDAT)? Arch Gerontol Geriatr 21:63–74
19. Heo JH, Lee SR, Lee ST, Lee KM, Oh JH, Jang DP, Chang KT, Cho ZH (2011) Spatial distribution of glucose hypometabolism induced by intracerebroventricular streptozotocin in monkeys. J Alzheimers Dis 25:517–523
20. Hong M, Chen DC, Klein PS, Lee VM (1997) Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3. J Biol Chem 272:25326–25332
21. Hoyer S (1994) Neurodegeneration, Alzheimer’s disease, and beta-amyloid toxicity. Life Sci 55:1977–1983
22. Hoyer S (1998) Is sporadic Alzheimer disease the brain type of non-insulin dependent diabetes mellitus? A challenging hypothesis. J Neural Transm 105:415–422
23. Hoyer S (2002) The brain insulin signal transduction system and sporadic (type II) Alzheimer disease: an update. J Neural Transm 109:341–360
24. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490:115–125
25. Ishiguro K, Shiratsuchi A, Sato S, Omori A, Arioka M, Kobayashi S, Uchida T, Imahori K (1993) Glycogen synthase kinase 3 beta is identical to tau protein kinase I generation several epitopes of paired helical filaments. FEBS Letter 325:167–172
26. Kadowaki T, Kasuga M, Akanuma Y, Ezaki O, Takaku F (1984) Decreased autophosphorylation of the insulin receptor-kinase in streptozotocin-diabetic rats. J Biol Chem 259:14208–14216
27. Lannert H, Hoyer S (1998) Intracerebroventricular administration of streptozotocin causes long-term diminutions in learning and memory abilities and in cerebral energy metabolism in adult rats. Behav Neurosci 112:1199–1208
28. Lee Y, Kim YH, Park SJ, Huh JW, Kim SH, Kim SU, Kim JS, Jeong KJ, Lee KM, Hong Y, Lee SR, Chang KT (2014) Insulin/IGF signaling-related gene expression in the brain of a sporadic Alzheimer’s disease monkey model induced by intracerebroventricular injection of streptozotocin. J Alzheimers Dis 38:251–267
29. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer’s disease. J Alzheimers Dis 9:13–33
30. Liao MH, Xiang YC, Huang JY, Tao RR, Tian Y, Ye WF, Zhang GS, Lu YM, Ahmed MM, Liu ZR, Fukunaga K, Han F (2013) The disturbance of hippocampal CaMKII/PKA/PKC phosphorylation in early experimental diabetes mellitus. CNS Neurosci Ther 19:329–336
31. Liu P, Zou L, Jiao Q, Chi T, Ji X, Qi Y, Xu Q, Wang L (2013) Xanthoceraside attenuates learning and memory deficits via improving insulin signaling in STZ-induced AD rats. Neurosci Lett 543:115–120
32. McCubrey JA, Steelman LS, Bertrand FE, Davis NM, Sokolosky M, Abrams SL, Montalto G, D’Assoro AB, Libra M, Nicoletti F, Maestro R, Basecke J, Rakus D, Gizak A, Demidenko ZN, Cocco L, Martelli AM, Cervello M (2014) GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget 5:2881–2911
33. Nelson PT, Braak H, Markesbery WR (2009) Neuropathology and cognitive impairment in Alzheimer disease: a complex but coherent relationship. J Neuropathol Exp Neurol 68:1–14
34. Nitsch R, Hoyer S (1991) Local action of the diabetogenic drug, streptozotocin, on glucose and energy metabolism in rat brain cortex. Neurosci Lett 128:199–202
35. Noble EP, Wurtman RJ, Axelrod J (1967) A simple and rapid method for injecting H3-norepinephrine into the lateral ventricle of the ratbrain. Life Sci 6:281–291
36. Park SJ, Kim YH, Lee Y, Kim KM, Kim HS, Lee SR, Kim SU, Kim SH, Kim JS, Jeong KJ, Lee KM, Huh JW, Chang KT (2013) Selection of appropriate reference genes for RT-qPCR analysis in a streptozotocin-induced Alzheimer’s disease model of cynomolgus monkeys (Macaca fascicularis). PLoS One 8:e56034
37. Paz K, Voliovitch H, Hadari YR, Roberts CT Jr, LeRoith D, Zick Y (1996) Interaction between the insulin receptor and its downstream effectors. Use of individually expressed receptor domains for structure/function analysis. J Biol Chem 271:6998–7003
38. Pei JJ, Tanaka T, Tung YC, Braak E, Iqbala K, Grundke-Iqbala I (1997) Distribution, levels, and activity of glycogen synthase kinase 3 in the Alzheimer disease brain. J Neuropathol Exp Neurol 56:70–78
39. Plasche K, Hoyer S (1993) Action of the diabetogenic drug streptozotocin on glycolytic metabolism in adult rat brain cortex and hippocampus. Int J Dev Neurosci 11:477–483
40. Plattner F, Angelo M, Giese KP (2006) The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation. J Biol Chem 281:25457–25465
41. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer’s disease: review and hypothesis. Neurobiol Aging 27:190–198
42. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF (2004) Akt activity in Alzheimer’s disease and other neurodegenerative disorders. Neuro Rep 15:955–959
43. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signalling pathway. J Neurochem 96:1005–1015
44. Salkovic-Petrisic M, Osmanovic-Barilar J, Brückner MK, Hoyer S, Arendt T, Riederer P (2011) Cerebral amyloid angiopathy in streptozotocin rat model of sporadic Alzheimer’s disease: a long-term follow up study. J Neural Transm 118:765–772
45. Saltiel AR, Pessin JE (2002) Insulin signaling pathways in time and space. Trends Cell Biol 12:65–71
46. Santos TO, Mazucanti CH, Xavier GF, Torrão AS (2012) Early and late neurodegeneration and memory disruption after intracerebroventricular streptozotocin. Physiol Behav 107:401–413
47. Schneppenheim R, Budde U, Dahlmann N, Rautenberg P (1991) Luminography—a new, highly sensitive visualization method for electrophoresis. Electrophoresis 1:367–372
48. Shingo AS, Kanabayashi T, Murase T, Kito S (2012) Cognitive decline in STZ-3 V rats is largely due to dysfunctional insulin signalling through the dentate gyrus. Behav Brain Res 229:378–383
49. Shonesy BC, Thiruchelvam K, Parameshwaran K, Rahman EA, Karuppagounder SS, Huggins KW, Pinkert CA, Amin R, Dhanasekaran M, Suppiramaniam V (2012) Central insulin resistance and synaptic dysfunction in intracerebroventricular-streptozotocin injected rodents. Neurobiol Aging 33(430):e5–18
50. Sodhi RK, Singh N (2013) All-trans retinoic acid rescues memory deficits and neuropathological changes in mouse model of streptozotocin-induced dementia of Alzheimer’s type. Prog Neuropsychopharmacol Biol Psychiatry 40:38–46
51. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, Xu XJ, Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer′s disease-is this type 3 diabetes? J Alzheimer′s Dis 7:63–80
52. Szkudelski T (2001) The mechanism of alloxan and streptozotocin action in B cell of the rat pancreas. Physiol Res 50:537–546
53. Takahashi M, Iseki E, Kosaka K (2000) Cdk5 and munc-18/p67 co-localization in early stage neurofibrillary tangles-bearing neurons in Alzheimer type dementia brains. J Neurol Sci 172:63–69
54. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, Speleman F (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034
55. Wang S, Zhou SL, Min FY, Ma JJ, Shi XJ, Bereczki E, Wu J (2014) mTOR-mediated hyperphosphorylation of tau in the hippocampus is involved in cognitive deficits in streptozotocin-induced diabetic mice. Metab Brain Dis 29:729–736
56. Wen Y, Planel E, Herman M, Figueroa HY, Wang L, Liu L, Lau LF, Yu WH, Duff KE (2008) Interplay between cyclin-dependent kinase 5 and glycogen synthase kinase 3 beta mediated by neuregulin signaling leads to differential effects on tau phosphorylation and amyloid precursor protein processing. J Neurosci 28:2624–2632
57. Yang W, Ma J, Liu Z, Lu Y, Hu B, Yu H (2014) Effect of naringenin on brain insulin signaling and cognitive functions in ICV-STZ induced dementia model of rats. Neurol Sci 35:741–751
58. Zhao WQ, Alkon DL (2001) Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol 177:125–134
59. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy SA, Cole GM (2004a) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer’s disease intervention. J Neurosci 24:11120–11126
60. Zhao WQ, Chen H, Quon MJ, Alkon DL (2004b) Insulin and the insulin receptor in experimental models of learning and memory. Eur J Pharmacol 490:71–81